伊布替尼治疗复发/难治性滤泡性淋巴瘤患者:开放标签、多中心、II期DAWN研究结果
DAWN研究为开放标签、单臂、II期研究,纳入110例既往≥2线治疗的复发/难治性滤泡性淋巴瘤患者,接受伊布替尼560 mg每日一次。中位随访27.7个月,独立评审委员会评估的总体缓解率为20.9%(95% CI 13.7%–29.7%),未达到主要终点预设的18%下限阈值;12例(11%)达完全缓解,中位缓解持续时间19.4个月,中位无进展生存期4.6个月,30个月总生存率61%。
要点
- 伊布替尼560 mg每日一次治疗复发/难治性滤泡性淋巴瘤的总体缓解率为20.9%,未达到主要终点。
- 12例(11%)达完全缓解,中位缓解持续时间19.4个月,中位无进展生存期4.6个月。
- 48.2%患者报告严重不良事件;缓解者调节性T细胞下调且干扰素-γ、白细胞介素-12升高。
核心结论
- 在复发/难治性滤泡性淋巴瘤患者中,伊布替尼单药治疗的总体缓解率为20.9%,未达到主要疗效终点,但缓解持久,且与调节性T细胞减少及促炎细胞因子升高相关。
研究设计与样本
- DAWN研究为开放标签、单臂、II期研究,纳入既往接受≥2线治疗的复发/难治性滤泡性淋巴瘤患者110例,接受伊布替尼560 mg每日一次直至疾病进展或不可接受毒性。
- 主要终点为独立评审委员会评估的总体缓解率(完全缓解+部分缓解)。
- 对可用样本进行外周血T细胞亚群(基线/第3周期)及细胞因子/趋化因子(基线/第2周期)的探索性分析。
主要发现
- 2013年3月至2016年5月入组110例患者,既往治疗中位线数为3线;中位随访27.7个月。
- 总体缓解率为20.9%(95% CI 13.7%–29.7%),未达到主要终点预设的18%下限阈值;12例(11%;95% CI 5.8%–18.3%)达完全缓解。
- 中位缓解持续时间为19.4个月(范围1至≥33个月),中位无进展生存期为4.6个月,30个月总生存率为61%(95% CI 0.51%–0.70%)。
- 淋巴瘤症状缓解者占67%;32例出现初始影像学进展的患者中,7例继续治疗后缓解(假性进展)。
- 最常见不良事件为腹泻、乏力、咳嗽和肌肉痉挛;48.2%患者报告严重不良事件。
关键数值与推荐
- 主要终点总体缓解率20.9%(95% CI 13.7%–29.7%),未达到18%下限阈值;完全缓解率11%(95% CI 5.8%–18.3%)。
- 中位缓解持续时间19.4个月(范围1至≥33个月),中位无进展生存期4.6个月,30个月总生存率61%(95% CI 0.51%–0.70%)。
- 淋巴瘤症状缓解率67%;32例初始影像学进展者中7例继续治疗后缓解。
- 缓解者第3周期第1天调节性T细胞下调(P=0.02),干扰素-γ和白细胞介素-12升高(P≤0.035)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee-assessed overall response rate (ORR; complete response plus partial response). Exploratory analyses of T-cell subsets in peripheral blood (baseline/cycle 3) and cytokines/chemokines (baseline/cycle 2) were performed for available samples. Results Between March 2013 and May 2016, 110 patients with a median of three prior lines of therapy were enrolled. At median follow-up of 27.7 months, ORR was 20.9% (95% CI, 13.7% to 29.7%, which did not meet the 18% lower-bound threshold for the primary end point). Twelve patients achieved a complete response (11%; 95% CI, 5.8% to 18.3%). Median duration of response was 19.4 months (range, 1 to ≥ 33 months), with a median progression-free survival of 4.6 months and a 30-month overall survival of 61% (95% CI, 0.51% to 0.70%). Lymphoma symptoms resolved in 67%. Seven of 32 patients who experienced initial radiologic progression responded upon continuing therapy (pseudoprogression). The most common adverse events were diarrhea, fatigue, cough, and muscle spasms; 48.2% of patients reported serious adverse events. In patients who experienced a response, regulatory T cells were downregulated at C3D1 ( P = .02), and Th1-promoting (antitumor) cytokines interferon-γ and interleukin-12 increased ( P ≤ .035). Conclusion With an ORR of 20.9%, ibrutinib failed to meet its primary efficacy end point in chemoimmunotherapy in patients with relapsed/refractory FL, although responses were durable and associated with a reduction in regulatory T cells and increases in proinflammatory cytokines.
引用
- Gopal AK, Schuster SJ, Fowler NH, et al. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol. 2018. PMID: 29851546. doi:10.1200/JCO.2017.76.8853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。